Analysts Set Fulcrum Therapeutics, Inc. (NASDAQ:FULC) PT at $19.00

Posted by on May 29th, 2026

Fulcrum Therapeutics, Inc. (NASDAQ:FULC – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $19.00.

A number of equities analysts have issued reports on the company. Leerink Partners restated an “outperform” rating on shares of Fulcrum Therapeutics in a report on Tuesday, February 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research note on Tuesday, April 21st. Truist Financial set a $17.00 target price on Fulcrum Therapeutics in a research report on Tuesday, February 24th. Finally, Wall Street Zen raised Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 2nd.

View Our Latest Report on Fulcrum Therapeutics

Institutional Trading of Fulcrum Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of FULC. Mirae Asset Global Investments Co. Ltd. bought a new stake in Fulcrum Therapeutics in the fourth quarter valued at approximately $30,000. Quarry LP bought a new stake in Fulcrum Therapeutics in the third quarter valued at approximately $35,000. Meeder Asset Management Inc. bought a new stake in Fulcrum Therapeutics in the fourth quarter valued at approximately $39,000. Summit Securities Group LLC bought a new stake in Fulcrum Therapeutics in the first quarter valued at approximately $53,000. Finally, Russell Investments Group Ltd. lifted its position in Fulcrum Therapeutics by 4,209.3% in the second quarter. Russell Investments Group Ltd. now owns 9,308 shares of the company’s stock valued at $64,000 after purchasing an additional 9,092 shares during the last quarter. Institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Trading Up 0.6%

FULC stock opened at $6.82 on Friday. The stock has a market capitalization of $454.42 million, a P/E ratio of -5.93 and a beta of 3.02. Fulcrum Therapeutics has a 12 month low of $5.88 and a 12 month high of $15.74. The firm has a 50-day moving average price of $7.24 and a 200-day moving average price of $9.24.

Fulcrum Therapeutics (NASDAQ:FULC – Get Free Report) last released its quarterly earnings data on Monday, April 27th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.06. As a group, equities analysts predict that Fulcrum Therapeutics will post -1.16 EPS for the current fiscal year.

Fulcrum Therapeutics Company Profile

(Get Free Report)

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.

Read More

Analyst Recommendations for Fulcrum Therapeutics (NASDAQ:FULC)

Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.